Encompass Health’s (EHC) Outperform Rating Reiterated at William Blair

William Blair reiterated their outperform rating on shares of Encompass Health (NYSE:EHC) in a report published on Friday,RTT News reports. William Blair also issued estimates for Encompass Health’s Q1 2025 earnings at $1.16 EPS, Q2 2025 earnings at $1.12 EPS, Q3 2025 earnings at $1.14 EPS, Q4 2025 earnings at $1.32 EPS and FY2026 earnings at $5.39 EPS.

Several other research analysts have also weighed in on EHC. Royal Bank of Canada lifted their price objective on Encompass Health from $105.00 to $110.00 and gave the stock an “outperform” rating in a research report on Wednesday, October 30th. Barclays lifted their target price on shares of Encompass Health from $109.00 to $116.00 and gave the stock an “overweight” rating in a research report on Tuesday, October 29th. KeyCorp upped their price target on Encompass Health from $115.00 to $117.00 and gave the company an “overweight” rating in a research report on Tuesday, October 29th. Finally, Truist Financial reiterated a “buy” rating and issued a $116.00 target price (up from $108.00) on shares of Encompass Health in a research note on Wednesday, October 30th. One equities research analyst has rated the stock with a hold rating, nine have issued a buy rating and two have given a strong buy rating to the company’s stock. Based on data from MarketBeat, Encompass Health currently has a consensus rating of “Buy” and an average price target of $107.33.

Encompass Health Trading Up 1.3 %

Shares of Encompass Health stock opened at $99.86 on Friday. Encompass Health has a 12-month low of $72.37 and a 12-month high of $104.55. The company has a market capitalization of $10.06 billion, a price-to-earnings ratio of 22.39, a PEG ratio of 1.18 and a beta of 0.90. The company has a quick ratio of 1.04, a current ratio of 1.04 and a debt-to-equity ratio of 0.88. The firm’s 50-day moving average price is $96.28 and its two-hundred day moving average price is $95.30.

Encompass Health (NYSE:EHC) last issued its earnings results on Thursday, February 6th. The company reported $1.17 earnings per share for the quarter, beating analysts’ consensus estimates of $1.05 by $0.12. Encompass Health had a net margin of 8.48% and a return on equity of 18.06%. On average, analysts forecast that Encompass Health will post 4.76 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Encompass Health

A number of large investors have recently added to or reduced their stakes in EHC. MassMutual Private Wealth & Trust FSB grew its holdings in Encompass Health by 87.8% in the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 293 shares of the company’s stock worth $27,000 after purchasing an additional 137 shares during the period. UMB Bank n.a. boosted its position in shares of Encompass Health by 387.7% in the third quarter. UMB Bank n.a. now owns 317 shares of the company’s stock worth $31,000 after purchasing an additional 252 shares during the period. V Square Quantitative Management LLC lifted its holdings in Encompass Health by 53.0% in the 3rd quarter. V Square Quantitative Management LLC now owns 404 shares of the company’s stock worth $39,000 after purchasing an additional 140 shares in the last quarter. Avior Wealth Management LLC purchased a new stake in shares of Encompass Health in the third quarter worth about $40,000. Finally, Tompkins Financial Corp purchased a new position in shares of Encompass Health in the 4th quarter worth $46,000. Institutional investors own 97.25% of the company’s stock.

About Encompass Health

Encompass Health Corporation provides post-acute healthcare services in the United States and Puerto Rico. It owns and operates inpatient rehabilitation hospitals that provide medical, nursing, therapy, and ancillary services. The company provides specialized rehabilitative treatment on an inpatient basis to patients who have experienced physical or cognitive disabilities or injuries due to medical conditions, such as strokes, hip fractures, and various debilitating neurological conditions.